Skip to main content

Table 3 Baseline characteristics of patients

From: A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment

Characteristics

Intratympanic Dex (n = 58)

Topical IGF-1 (n = 60)

Pvalue

Age-yr, mean ± SD

50.1 ± 13.0

48.6 ± 14.0

0.557

Male sex-no. (%)

26 (44.8)

28 (46.7)

0.855

No. of days for study entry from onset, mean (95% CI)

16.3 (15.1-17.5)

15.8 (14.6-17.0)

0.574

Hearing improvement by pre-treatment-no. (%)

   

>10 dB, <30 dB

13 (22.4)

17 (28.3)

0.528

<10 dB

45 (77.6)

43 (71.7)

Hearing-dB pure-tone average, mean (95% CI)

   

Affected ear

84.8 (79.1-90.4)

85.6 (80.0-91.2)

0.835

Unaffected ear

15.8 (12.4-19.2)

20.4 (15.0-25.7)

0.160

Other symptoms-no. (%)

   

Dizziness/Vertigo

23 (39.7)

31 (51.7)

0.202

Tinnitus

49 (84.5)

51 (85)

>0.999

Aural fullness

44 (75.9)

32 (53.3)

0.013*

  1. An asterisk indicates statistical significance with Fisher’s exact test. Dex: dexamethasone.